Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes |
Apr 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Statin Use in Myelodysplastic Syndromes Is Associated with a Better Survival and Decreased Progression to Leukemia |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes |
Apr 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
Feb 2021 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |